首页 > 最新文献

Current Opinion in Urology最新文献

英文 中文
Metastasis-directed therapy in oligometastatic prostate cancer. 寡转移前列腺癌的转移导向疗法。
IF 2.5 3区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-05-01 Epub Date: 2024-03-05 DOI: 10.1097/MOU.0000000000001169
Marcin Miszczyk, Timo Soeterik, Giancarlo Marra, Akihiro Matsukawa, Shahrokh F Shariat

Purpose of review: To summarize the recent findings on the subject of metastasis-directed therapy (MDT) in the treatment of oligometastatic prostate cancer (omPCa).

Recent findings: Evidence from two randomized clinical trials (RCTs) and a meta-analysis show favorable toxicity profiles, and the potential to delay androgen-deprivation therapy (ADT) for up to two years in nearly half of patients with metachronous hormone-sensitive omPCa. Another RCT showed promising results of MDT as treatment-escalation method combined with androgen receptor signaling inhibitors (ARSI) in first-line treatment for castration-resistant omPCa.Surveys by radiation oncologists and consensus guidelines advocate for MDT across various omPCa scenarios. Multiple single-arm trials present encouraging results; however, the evidence for the benefit of MDT is still weak requiring further investigation to assess its impact on pivotal endpoints, such as survival and quality of life.

Summary: MDT is a promising approach in omPCa, and can be used to defer ADT in newly diagnosed metachronous omPCa patients, or to add to ARSI treatment at first diagnosis of castration-resistance. Ongoing prospective trials are needed to guide its optimal utilization in other settings, and patients should be informed about the evolving landscape of systemic therapies with proven survival benefits alongside MDT options.

综述的目的:总结转移导向疗法(MDT)治疗少转移性前列腺癌(omPCa)的最新研究成果:来自两项随机临床试验(RCT)和一项荟萃分析的证据显示,MDT具有良好的毒性特征,而且有可能使近半数对激素敏感的转移性前列腺癌患者的雄激素剥夺疗法(ADT)延迟长达两年。另一项研究表明,MDT 作为治疗升级方法与雄激素受体信号转导抑制剂(ARSI)相结合,在阉割耐药型 omPCa 的一线治疗中取得了良好的效果。多项单臂试验结果令人鼓舞;然而,MDT获益的证据仍然薄弱,需要进一步调查以评估其对生存期和生活质量等关键终点的影响。总结:MDT是治疗omPCa的一种很有前景的方法,可用于推迟新诊断的变异性omPCa患者的ADT,或在首次诊断出阉割耐药时加入ARSI治疗。需要不断进行前瞻性试验,以指导在其他情况下的最佳应用,同时应让患者了解不断发展的系统性疗法的情况,这些疗法已被证实可提高患者的生存率,并可与MDT疗法并用。
{"title":"Metastasis-directed therapy in oligometastatic prostate cancer.","authors":"Marcin Miszczyk, Timo Soeterik, Giancarlo Marra, Akihiro Matsukawa, Shahrokh F Shariat","doi":"10.1097/MOU.0000000000001169","DOIUrl":"10.1097/MOU.0000000000001169","url":null,"abstract":"<p><strong>Purpose of review: </strong>To summarize the recent findings on the subject of metastasis-directed therapy (MDT) in the treatment of oligometastatic prostate cancer (omPCa).</p><p><strong>Recent findings: </strong>Evidence from two randomized clinical trials (RCTs) and a meta-analysis show favorable toxicity profiles, and the potential to delay androgen-deprivation therapy (ADT) for up to two years in nearly half of patients with metachronous hormone-sensitive omPCa. Another RCT showed promising results of MDT as treatment-escalation method combined with androgen receptor signaling inhibitors (ARSI) in first-line treatment for castration-resistant omPCa.Surveys by radiation oncologists and consensus guidelines advocate for MDT across various omPCa scenarios. Multiple single-arm trials present encouraging results; however, the evidence for the benefit of MDT is still weak requiring further investigation to assess its impact on pivotal endpoints, such as survival and quality of life.</p><p><strong>Summary: </strong>MDT is a promising approach in omPCa, and can be used to defer ADT in newly diagnosed metachronous omPCa patients, or to add to ARSI treatment at first diagnosis of castration-resistance. Ongoing prospective trials are needed to guide its optimal utilization in other settings, and patients should be informed about the evolving landscape of systemic therapies with proven survival benefits alongside MDT options.</p>","PeriodicalId":11093,"journal":{"name":"Current Opinion in Urology","volume":" ","pages":"178-182"},"PeriodicalIF":2.5,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10990025/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139995898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The histomorphology of the senescent kidney - the clinical relevance of specimen and biopsy findings in the elderly native kidneys. 衰老肾脏的组织形态学--老年原生肾脏标本和活检结果的临床意义。
IF 2.5 3区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-05-01 Epub Date: 2024-02-26 DOI: 10.1097/MOU.0000000000001164
Nicolas Kozakowski

Purpose of review: Renal pathology is crucial in diagnosing the ageing kidney. Recent technological advances enabled high-resolution molecular investigations into the complex mechanisms of ageing and senescence.

Recent findings: The pathological analysis of large kidney tissue collections coupled with computer-assisted morphometry contributed to the establishment of age-related reference values for glomerular or vascular sclerosis, interstitial fibrosis, and tubular atrophy. Furthermore, new high-throughput proteomic and transcriptomic platforms have entered the field of pathology. When coupled with morphology information, these techniques facilitated the study of extracellular matrix modifications and the senescent immune system in the ageing kidney. Finally, iatrogenic complications are now frequent indications for diagnostic kidney biopsies in older patients, potentially accelerating kidney senescence.

Summary: Recent pathology literature supports identifying and prognosticating sclerosing processes in ageing kidneys.

综述的目的:肾脏病理学是诊断肾脏老化的关键。最近的技术进步使我们能够对老化和衰老的复杂机制进行高分辨率的分子研究:大量肾脏组织收集的病理分析与计算机辅助形态测量相结合,有助于建立肾小球或血管硬化、肾间质纤维化和肾小管萎缩的年龄相关参考值。此外,新的高通量蛋白质组和转录组平台已进入病理学领域。这些技术与形态学信息相结合,促进了对衰老肾脏中细胞外基质修饰和衰老免疫系统的研究。最后,先天性并发症现已成为老年患者诊断性肾脏活检的常见指征,有可能加速肾脏衰老:最近的病理学文献支持对衰老肾脏的硬化过程进行识别和预后。
{"title":"The histomorphology of the senescent kidney - the clinical relevance of specimen and biopsy findings in the elderly native kidneys.","authors":"Nicolas Kozakowski","doi":"10.1097/MOU.0000000000001164","DOIUrl":"10.1097/MOU.0000000000001164","url":null,"abstract":"<p><strong>Purpose of review: </strong>Renal pathology is crucial in diagnosing the ageing kidney. Recent technological advances enabled high-resolution molecular investigations into the complex mechanisms of ageing and senescence.</p><p><strong>Recent findings: </strong>The pathological analysis of large kidney tissue collections coupled with computer-assisted morphometry contributed to the establishment of age-related reference values for glomerular or vascular sclerosis, interstitial fibrosis, and tubular atrophy. Furthermore, new high-throughput proteomic and transcriptomic platforms have entered the field of pathology. When coupled with morphology information, these techniques facilitated the study of extracellular matrix modifications and the senescent immune system in the ageing kidney. Finally, iatrogenic complications are now frequent indications for diagnostic kidney biopsies in older patients, potentially accelerating kidney senescence.</p><p><strong>Summary: </strong>Recent pathology literature supports identifying and prognosticating sclerosing processes in ageing kidneys.</p>","PeriodicalId":11093,"journal":{"name":"Current Opinion in Urology","volume":" ","pages":"170-175"},"PeriodicalIF":2.5,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139971261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Definitions, outcomes and perspectives for oligometastatic bladder cancer: towards a standardized terminology. 寡转移性膀胱癌的定义、结果和前景:实现术语标准化。
IF 2.5 3区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-05-01 Epub Date: 2024-02-29 DOI: 10.1097/MOU.0000000000001170
Giorgio Calleris, Markus von Deimling, Claudia Kesch, Francesco Soria, Paolo Gontero, Guillaume Ploussard, Ekaterina Laukhtina, Benjamin Pradere

Purpose of review: Oligometastatic (om) cancer is considered as a transitional state in between locally confined disease and widespread metastases, accessible to a multimodal treatment, combining systemic and local therapy. In urothelial bladder cancer (BCa), the definitions and the approaches to this condition are poorly standardised and mainly based on retrospective data. We aim to portray the framework for uro-oncologic terminology in omBCa and go through the latest evidence and the future perspectives.

Recent findings: Retrospective and registry data support the potential benefits of multimodality treatment for carefully selected omBCa patients, especially following a good response to systemic treatment. In 2023, a Delphi consensus has defined omBCa, allowing maximum three metastatic lesions, theoretically amenable to radical local treatment. In de-novo omBCa, surgical treatment of primary tumour might improve overall survival (OS), according to a matched registry analysis; also, consolidative radiotherapy was associated with better OS in two recent cohorts. Furthermore, metastasis-directed therapy (MDT) has shown high local control rates and promising OS (14.9-51 months) in a meta-analysis; benefits might be more pronounced for single-site omBCa and nodal or lung lesions.

Summary: From a clinical perspective, in de-novo omBCa, the local treatment of primary and metastatic sites might improve disease control and survival, in selected patients; in the oligorecurrent setting, MDT achieves good local symptom control with limited side effects; in selected cases, it could convey a survival benefit, too. From a research perspective, well designed prospective evidence is eagerly awaited, based on recently adopted shared definitions for omBCa.

综述目的:寡转移(om)癌症被认为是介于局部局限性疾病和广泛转移之间的一种过渡状态,可接受结合全身和局部治疗的多模式疗法。在尿路上皮性膀胱癌(BCa)中,对这种情况的定义和治疗方法标准化程度很低,而且主要基于回顾性数据。我们旨在描绘omBCa的泌尿肿瘤学术语框架,并回顾最新证据和未来展望:回顾性数据和登记数据支持多模式治疗对精心挑选的omBCa患者的潜在益处,尤其是对全身治疗有良好反应的患者。2023 年,德尔菲共识对 omBCa 进行了定义,最多允许有三个转移病灶,理论上可以进行局部根治性治疗。根据一项配对登记分析,对于新发的 omBCa,原发肿瘤的手术治疗可能会提高总生存率(OS);在最近的两个队列中,巩固性放疗也与更好的 OS 有关。此外,在一项荟萃分析中,转移导向疗法(MDT)显示出较高的局部控制率和良好的生存期(14.9-51 个月);对于单发部位 omBCa 和结节或肺部病变,其益处可能更为明显:小结:从临床角度看,对于新发的 omBCa,对原发和转移部位进行局部治疗可能会改善选定患者的疾病控制和生存率;在少发的情况下,MDT 可以很好地控制局部症状,且副作用有限;在选定的病例中,MDT 也可能带来生存率的提高。从研究的角度来看,我们急切地期待着根据最近通过的 omBCa 共同定义而设计的前瞻性证据。
{"title":"Definitions, outcomes and perspectives for oligometastatic bladder cancer: towards a standardized terminology.","authors":"Giorgio Calleris, Markus von Deimling, Claudia Kesch, Francesco Soria, Paolo Gontero, Guillaume Ploussard, Ekaterina Laukhtina, Benjamin Pradere","doi":"10.1097/MOU.0000000000001170","DOIUrl":"10.1097/MOU.0000000000001170","url":null,"abstract":"<p><strong>Purpose of review: </strong>Oligometastatic (om) cancer is considered as a transitional state in between locally confined disease and widespread metastases, accessible to a multimodal treatment, combining systemic and local therapy. In urothelial bladder cancer (BCa), the definitions and the approaches to this condition are poorly standardised and mainly based on retrospective data. We aim to portray the framework for uro-oncologic terminology in omBCa and go through the latest evidence and the future perspectives.</p><p><strong>Recent findings: </strong>Retrospective and registry data support the potential benefits of multimodality treatment for carefully selected omBCa patients, especially following a good response to systemic treatment. In 2023, a Delphi consensus has defined omBCa, allowing maximum three metastatic lesions, theoretically amenable to radical local treatment. In de-novo omBCa, surgical treatment of primary tumour might improve overall survival (OS), according to a matched registry analysis; also, consolidative radiotherapy was associated with better OS in two recent cohorts. Furthermore, metastasis-directed therapy (MDT) has shown high local control rates and promising OS (14.9-51 months) in a meta-analysis; benefits might be more pronounced for single-site omBCa and nodal or lung lesions.</p><p><strong>Summary: </strong>From a clinical perspective, in de-novo omBCa, the local treatment of primary and metastatic sites might improve disease control and survival, in selected patients; in the oligorecurrent setting, MDT achieves good local symptom control with limited side effects; in selected cases, it could convey a survival benefit, too. From a research perspective, well designed prospective evidence is eagerly awaited, based on recently adopted shared definitions for omBCa.</p>","PeriodicalId":11093,"journal":{"name":"Current Opinion in Urology","volume":" ","pages":"217-224"},"PeriodicalIF":2.5,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139995896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preclinical models for bladder cancer therapy research. 膀胱癌治疗研究的临床前模型。
IF 2.5 3区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-04-17 DOI: 10.1097/mou.0000000000001182
Iris Ertl, Shahrokh F Shariat, Walter Berger, Bernard Englinger
Bladder cancer (BC) is a highly heterogenous disease comprising tumours of various molecular subtypes and histologic variants. This heterogeneity represents a major challenge for the development of novel therapeutics. Preclinical models that closely mimic in vivo tumours and reflect their diverse biology are indispensable for the identification of therapies with specific activity in various BC subtypes. In this review, we summarize efforts and progress made in this context during the last 24 months.
膀胱癌(BC)是一种高度异质性疾病,包括各种分子亚型和组织学变异的肿瘤。这种异质性是开发新型疗法的一大挑战。密切模拟体内肿瘤并反映其多样化生物学特性的临床前模型对于确定对各种膀胱癌亚型具有特异性活性的疗法是不可或缺的。在本综述中,我们将总结过去 24 个月中在这方面所做的努力和取得的进展。
{"title":"Preclinical models for bladder cancer therapy research.","authors":"Iris Ertl, Shahrokh F Shariat, Walter Berger, Bernard Englinger","doi":"10.1097/mou.0000000000001182","DOIUrl":"https://doi.org/10.1097/mou.0000000000001182","url":null,"abstract":"Bladder cancer (BC) is a highly heterogenous disease comprising tumours of various molecular subtypes and histologic variants. This heterogeneity represents a major challenge for the development of novel therapeutics. Preclinical models that closely mimic in vivo tumours and reflect their diverse biology are indispensable for the identification of therapies with specific activity in various BC subtypes. In this review, we summarize efforts and progress made in this context during the last 24 months.","PeriodicalId":11093,"journal":{"name":"Current Opinion in Urology","volume":"4 1","pages":""},"PeriodicalIF":2.5,"publicationDate":"2024-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140623503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advances in preclinical assessment of therapeutic targets for bladder cancer precision medicine. 膀胱癌精准医学治疗靶点的临床前评估进展。
IF 2.5 3区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-04-11 DOI: 10.1097/mou.0000000000001177
Christoph Nössing, Paula Herek, Shahrokh F Shariat, Walter Berger, Bernhard Englinger
Bladder cancer incidence is on the rise, and until recently, there has been little to no change in treatment regimens over the last 40 years. Hence, it is imperative to work on strategies and approaches to untangle the complexity of intra and inter-tumour heterogeneity of bladder cancer with the aim of improving patient-specific care and treatment outcomes. The focus of this review is therefore to highlight novel targets, advances, and therapy approaches for bladder cancer patients.
膀胱癌的发病率呈上升趋势,而直到最近,过去 40 年来治疗方案几乎没有任何变化。因此,当务之急是研究各种策略和方法,以解决膀胱癌肿瘤内和肿瘤间异质性的复杂性,从而改善针对患者的护理和治疗效果。因此,本综述的重点是突出膀胱癌患者的新靶点、进展和治疗方法。
{"title":"Advances in preclinical assessment of therapeutic targets for bladder cancer precision medicine.","authors":"Christoph Nössing, Paula Herek, Shahrokh F Shariat, Walter Berger, Bernhard Englinger","doi":"10.1097/mou.0000000000001177","DOIUrl":"https://doi.org/10.1097/mou.0000000000001177","url":null,"abstract":"Bladder cancer incidence is on the rise, and until recently, there has been little to no change in treatment regimens over the last 40 years. Hence, it is imperative to work on strategies and approaches to untangle the complexity of intra and inter-tumour heterogeneity of bladder cancer with the aim of improving patient-specific care and treatment outcomes. The focus of this review is therefore to highlight novel targets, advances, and therapy approaches for bladder cancer patients.","PeriodicalId":11093,"journal":{"name":"Current Opinion in Urology","volume":"278 1","pages":""},"PeriodicalIF":2.5,"publicationDate":"2024-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140588156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antegrade ejaculation preservation in surgical treatment for benign prostatic hyperplasia: quest for balance between voiding and sexual function. 良性前列腺增生手术治疗中的逆行射精保留:寻求排尿和性功能之间的平衡。
IF 2.5 3区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-04-10 DOI: 10.1097/mou.0000000000001178
Diana M Lopategui, Hemendra N Shah, Thomas R W Herrmann
Surgical treatment of benign prostatic hyperplasia (BPH) carries a significant risk of ejaculation dysfunction. Preservation of antegrade ejaculation while providing effective, well tolerated, and durable treatment of BPH is a paramount component of physical and sexual well being for significant number of men. We reviewed available literature with an aim of providing status on antegrade ejaculation preserving BPH surgical therapies.
良性前列腺增生症(BPH)的手术治疗存在射精功能障碍的重大风险。在对良性前列腺增生症进行有效、耐受性良好且持久的治疗的同时,保留逆行射精是众多男性身体健康和性健康的重要组成部分。我们回顾了现有文献,旨在提供有关保留逆行射精的良性前列腺增生手术疗法的现状。
{"title":"Antegrade ejaculation preservation in surgical treatment for benign prostatic hyperplasia: quest for balance between voiding and sexual function.","authors":"Diana M Lopategui, Hemendra N Shah, Thomas R W Herrmann","doi":"10.1097/mou.0000000000001178","DOIUrl":"https://doi.org/10.1097/mou.0000000000001178","url":null,"abstract":"Surgical treatment of benign prostatic hyperplasia (BPH) carries a significant risk of ejaculation dysfunction. Preservation of antegrade ejaculation while providing effective, well tolerated, and durable treatment of BPH is a paramount component of physical and sexual well being for significant number of men. We reviewed available literature with an aim of providing status on antegrade ejaculation preserving BPH surgical therapies.","PeriodicalId":11093,"journal":{"name":"Current Opinion in Urology","volume":"23 1","pages":""},"PeriodicalIF":2.5,"publicationDate":"2024-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140587984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Definitions and unmet needs in the management of oligomestatic renal cell carcinoma in the modern era. 现代治疗少瘤型肾细胞癌的定义和未满足的需求。
IF 2.5 3区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-04-09 DOI: 10.1097/mou.0000000000001179
Giulio Francolini, Riccardo Campi, Chiara Ciccarese
Oligometastatic renal cell carcinoma (RCC) is a complex entity, potentially leading to a specific clinical management of these patients. Recent and ongoing trials have raised several unresolved questions that could impact clinical routine practice, advocating for the integration of novel treatment options (systemic treatment, cytoreductive surgery, or stereotactic body radiotherapy - SBRT) with varied modalities and objectives.
寡转移性肾细胞癌(RCC)是一个复杂的实体,有可能导致对这些患者的特殊临床管理。最近和正在进行的试验提出了一些尚未解决的问题,这些问题可能会影响到临床常规治疗,因此提倡将新的治疗方案(全身治疗、细胞修复手术或立体定向体放射治疗 - SBRT)与不同的模式和目标相结合。
{"title":"Definitions and unmet needs in the management of oligomestatic renal cell carcinoma in the modern era.","authors":"Giulio Francolini, Riccardo Campi, Chiara Ciccarese","doi":"10.1097/mou.0000000000001179","DOIUrl":"https://doi.org/10.1097/mou.0000000000001179","url":null,"abstract":"Oligometastatic renal cell carcinoma (RCC) is a complex entity, potentially leading to a specific clinical management of these patients. Recent and ongoing trials have raised several unresolved questions that could impact clinical routine practice, advocating for the integration of novel treatment options (systemic treatment, cytoreductive surgery, or stereotactic body radiotherapy - SBRT) with varied modalities and objectives.","PeriodicalId":11093,"journal":{"name":"Current Opinion in Urology","volume":"27 1","pages":""},"PeriodicalIF":2.5,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140587986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of cytoreductive radical prostatectomy in men with oligometastatic prostate cancer on molecular imaging. 根据分子成像对少转移性前列腺癌患者进行细胞根治性前列腺切除术的作用。
IF 2.5 3区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-04-08 DOI: 10.1097/mou.0000000000001180
Daniele Robesti, Andrea Gallina, Francesco Montorsi, Alberto Briganti, Nicola Fossati
The implementation of PET with prostate-specific membrane antigen (PSMA) tracer as primary staging tool occurred recently. Since its introduction, a novel category of patients emerged, with negative staging at conventional imaging, and positive molecular imaging. Local treatment in these patients might be associated with improved oncological outcomes when combined with systemic therapy. However, its impact on oligometastatic prostate cancer (omPCa) remains unknown. In this review, we aimed at investigating the role of cytoreductive radical prostatectomy (cRP) in oligometastatic disease at molecular imaging.
最近,前列腺特异性膜抗原(PSMA)示踪剂正电子发射计算机断层显像技术(PET)成为主要的分期工具。自该技术问世以来,出现了一类新的患者,他们的传统影像学分期为阴性,而分子影像学分期为阳性。对这类患者进行局部治疗并结合全身治疗,可能会改善肿瘤治疗效果。然而,该疗法对少转移性前列腺癌(omPCa)的影响仍然未知。在这篇综述中,我们旨在通过分子影像学检查研究细胞去势前列腺癌根治术(cRP)在少转移性疾病中的作用。
{"title":"Role of cytoreductive radical prostatectomy in men with oligometastatic prostate cancer on molecular imaging.","authors":"Daniele Robesti, Andrea Gallina, Francesco Montorsi, Alberto Briganti, Nicola Fossati","doi":"10.1097/mou.0000000000001180","DOIUrl":"https://doi.org/10.1097/mou.0000000000001180","url":null,"abstract":"The implementation of PET with prostate-specific membrane antigen (PSMA) tracer as primary staging tool occurred recently. Since its introduction, a novel category of patients emerged, with negative staging at conventional imaging, and positive molecular imaging. Local treatment in these patients might be associated with improved oncological outcomes when combined with systemic therapy. However, its impact on oligometastatic prostate cancer (omPCa) remains unknown. In this review, we aimed at investigating the role of cytoreductive radical prostatectomy (cRP) in oligometastatic disease at molecular imaging.","PeriodicalId":11093,"journal":{"name":"Current Opinion in Urology","volume":"60 1","pages":""},"PeriodicalIF":2.5,"publicationDate":"2024-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140588043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Is there a role for metastasis-directed therapy in bladder cancer? 转移导向疗法对膀胱癌有作用吗?
IF 2.5 3区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-04-05 DOI: 10.1097/mou.0000000000001174
Mohammad Abufaraj, Joud Al Karmi, Adan Bdeir
This article aims to comprehensively review and critique the existing literature on the role of metastatic-directed therapy in patients with metastatic bladder cancer, particularly in oligometastatic disease state.
本文旨在全面回顾和评论现有文献中关于转移导向疗法在转移性膀胱癌患者中的作用,尤其是在寡转移疾病状态下的作用。
{"title":"Is there a role for metastasis-directed therapy in bladder cancer?","authors":"Mohammad Abufaraj, Joud Al Karmi, Adan Bdeir","doi":"10.1097/mou.0000000000001174","DOIUrl":"https://doi.org/10.1097/mou.0000000000001174","url":null,"abstract":"This article aims to comprehensively review and critique the existing literature on the role of metastatic-directed therapy in patients with metastatic bladder cancer, particularly in oligometastatic disease state.","PeriodicalId":11093,"journal":{"name":"Current Opinion in Urology","volume":"39 1","pages":""},"PeriodicalIF":2.5,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140588042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radioguided surgery for lymph node metastases in prostate cancer. 前列腺癌淋巴结转移的放射引导手术。
IF 2.5 3区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-04-04 DOI: 10.1097/mou.0000000000001175
Sophie Knipper, Fabian Falkenbach, Tobias Maurer
This review highlights recent advancements in radioguided surgery (RGS) for prostate cancer. Our objective is to provide expert insights into the state of research, as reflected in the selected articles, and to offer perspectives on the clinical implications and future directions that emerge from this rapidly evolving domain.
这篇综述重点介绍了前列腺癌放射引导手术(RGS)的最新进展。我们的目的是提供专家对所选文章所反映的研究现状的见解,并对这一快速发展的领域所产生的临床影响和未来方向提出看法。
{"title":"Radioguided surgery for lymph node metastases in prostate cancer.","authors":"Sophie Knipper, Fabian Falkenbach, Tobias Maurer","doi":"10.1097/mou.0000000000001175","DOIUrl":"https://doi.org/10.1097/mou.0000000000001175","url":null,"abstract":"This review highlights recent advancements in radioguided surgery (RGS) for prostate cancer. Our objective is to provide expert insights into the state of research, as reflected in the selected articles, and to offer perspectives on the clinical implications and future directions that emerge from this rapidly evolving domain.","PeriodicalId":11093,"journal":{"name":"Current Opinion in Urology","volume":"50 1","pages":""},"PeriodicalIF":2.5,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140587985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Current Opinion in Urology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1